Related references
Note: Only part of the references are listed.Human papillomavirus vaccine against cervical cancer: Opportunity and challenge
Renjie Wang et al.
CANCER LETTERS (2020)
A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes-Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer
Partha Basu et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2018)
Tolerability of ADXS11-001 Lm-LLO Listeria-Based Immunotherapy With Mitomycin, Fluorouracil, and Radiation for Anal Cancer
Howard Safran et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress
John C. Flickinger et al.
VACCINES (2018)
Systemic listeriosis following vaccination with the attenuated Listeria monocytogenes therapeutic vaccine, ADXS11-001
Joseph J. Sacco et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer enhances HPV-specific T cell immunity
Rosemarie Krupar et al.
CANCER RESEARCH (2016)
Phase II study of ADXS11-001 in patients with persistent/recurrent, locoregional or metastatic squamous cell carcinoma of the anorectal canal.
Marwan Fakih et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
An In Vivo Selection Identifies Listeria monocytogenes Genes Required to Sense the Intracellular Environment and Activate Virulence Factor Expression
Michelle L. Reniere et al.
PLOS PATHOGENS (2016)
Global burden of cancers attributable to infections in 2012: a synthetic analysis
Martyn Plummer et al.
LANCET GLOBAL HEALTH (2016)
Perspectives for therapeutic HPV vaccine development
Andrew Yang et al.
JOURNAL OF BIOMEDICAL SCIENCE (2016)
Immunotherapy: An Evolving Paradigm in the Treatment of Advanced Cervical Cancer
Ramez N. Eskander et al.
CLINICAL THERAPEUTICS (2015)
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
Cornelia L. Trimble et al.
LANCET (2015)
Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer
Ezra EW Cohen et al.
Journal for ImmunoTherapy of Cancer (2015)
Identification of promiscuous HPV16-derived T helper cell epitopes for therapeutic HPV vaccine design
Agnieszka K. Grabowska et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Phase I study evaluating high dose ADXS11-001 treatment in women with carcinoma of the cervix.
Sharad A. Ghamande et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
ADXS-HPV: A therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen
Lori Cory et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
A phase 2 study of live-attenuated listens monocytogenes cancer immunotherapy (ADXS11-001) in the treatment of persistent or recurrent cancer of the cervix (GOG-0265).
Warner King Huh et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Listeria monocytogenes-Derived Listeriolysin O Has Pathogen-Associated Molecular Pattern-Like Properties Independent of Its Hemolytic Ability
Anu Wallecha et al.
CLINICAL AND VACCINE IMMUNOLOGY (2013)
Live-attenuated Listeria-based immunotherapy
John Rothman et al.
EXPERT REVIEW OF VACCINES (2013)
Listeriolysin O as a strong immunogenic molecule for the development of new anti-tumor vaccines
Rui Sun et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions
Peggy J. de Vos van Steenwijk et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Clinical Development of Listeria monocytogenes-Based Immunotherapies
Dung T. Le et al.
SEMINARS IN ONCOLOGY (2012)
Lm-LLO-Based Immunotherapies and HPV-Associated Disease
Anu Wallecha et al.
JOURNAL OF ONCOLOGY (2012)
Molecular biology of surface colonization by Listeria monocytogenes: an additional facet of an opportunistic Gram-positive foodborne pathogen
Sandra Renier et al.
ENVIRONMENTAL MICROBIOLOGY (2011)
Persistence of human papillomavirus infection: keys to malignant progression
Jason Bodily et al.
TRENDS IN MICROBIOLOGY (2011)
Local immune response in the microenvironment of CIN2-3 with and without spontaneous regression
Irene Tveiteras Ovestad et al.
MODERN PATHOLOGY (2010)
A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions
Susanne K. Kjaer et al.
CANCER PREVENTION RESEARCH (2009)
Human papilloma viruses and cancer in the post-vaccine era
E. Galani et al.
CLINICAL MICROBIOLOGY AND INFECTION (2009)
Host immune responses to cervical cancer
Swati Patel et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2009)
The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix
Paulo Cesar Maciag et al.
VACCINE (2009)
Development of a Listeria monocytogenes based vaccine against prostate cancer
Vafa Shahabi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection - A randomized trial
Allan Hildesheim et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Innate and adaptive immune responses to Listeria monocytogenes:: a short overview
Lauren A. Zenewicz et al.
MICROBES AND INFECTION (2007)
Adjuvant properties of listeriolysin O protein in a DNA vaccination strategy
Xiaohui Peng et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Cancer immunoediting from immune surveillance to immune escape
Ryungsa Kim et al.
IMMUNOLOGY (2007)
Simultaneous Th1-type cytokine expression is a signature of peritoneal CD4+ lymphocytes responding to infection with Listeria monocytogenes
MM Freeman et al.
JOURNAL OF IMMUNOLOGY (2005)
Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7
DA Sewell et al.
CANCER RESEARCH (2004)
The ability of two Listeria monocytogenes vaccines targeting human papillomavirus-16 E7 to induce an antitumor response correlates with myeloid dendritic cell function
XH Peng et al.
JOURNAL OF IMMUNOLOGY (2004)
Construction, characterization, and use of two Listeria monocytogenes site-specific phage integration vectors
P Lauer et al.
JOURNAL OF BACTERIOLOGY (2002)
Papillomaviruses and cancer: From basic studies to clinical application
H zur Hausen
NATURE REVIEWS CANCER (2002)
Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16
GR Gunn et al.
JOURNAL OF IMMUNOLOGY (2001)
Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8+ T-cell responses that home to the tumor site
A Lamikanra et al.
JOURNAL OF VIROLOGY (2001)
Share Paper
